Medtronic's Spin-off MiniMed to Invest $360 Million in New Diabetes Global Capability Center in Pune

Recently, Medtronic announced plans to invest in its facility located in Pune within five years.New Diabetes Global Capability Center (GCC)Investment of 4.3 billion rupees (approximately RMB360 million）。

Medtronic stated in a post on LinkedIn:

We are very honored to be in IndiaEstablishmentNew Global Competence Center for Diabetes, marking an important milestone we have reached ——This is a big step in the transformation of diabetes care.. This center embodies our unwavering commitment to advancing medical technology and providing meaningful innovations to improve people's lives.

Image source: Medtronic LinkedIn

For Medtronic, this investment in diabetes-related centers comes at a critical moment.

Medtronic announced plans to spin off its diabetes division at the end of last month, aiming to create a "more focused Medtronic."The newly separated company will be renamed "MiniMed".Restore the name of the insulin pump company it acquired in 2001.

Medtronic stated that choosing MiniMed as the name respects the company's roots and reflects a 40-year history of transformative diabetes care.

The new company's headquarters will remain in Northridge, California, with more than 8,000 employees. Currently, the diabetes business accounts for 8% of Medtronic's fiscal year 2025 revenue and 4% of the company's divisional operating profit.

In the future, MiniMed will continue to advance its business portfolio, which includes diabetes management tools such as automated insulin pumps, smart insulin pens, and continuous glucose monitors (CGM).

This Pune GCC aims to drive innovation and operational excellence, and is expected to create more than 300 service and software jobs in its first year of operation, with plans to double that number over the next four years.

Medtronic Diabetes Executive Vice President and President Que Dallara said, "In recent years, India has firmly established itself as a global leading IT hub. The abundance of talent in Pune and across India aligns with our mission – to provide solutions that truly make life easier for people with diabetes."

Medtronic stated that its diabetes GCC will also support patient financial services and operations, and the expansion in India will bring abundant job opportunities for these functional departments.

Its progress in diabetes products is also in full swing.Medtronic advanced its landmark partnership with Abbott in April by submitting an interoperable insulin pump to the FDA, connecting the insulin system with continuous glucose monitoring (CGM).

Last summer, the two companies announced a global partnership to pair Abbott's CGM with Medtronic's insulin delivery systems. This collaboration aims to co-develop a system based on Abbott's FreeStyle Libre CGM, integrating Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.

Medtronic's system previously utilized its self-developed CGM systems, such as the Guardian 4 and Simplera platforms, and the company plans to continue incorporating these systems as part of its integrated CGM product portfolio.

In addition to this collaboration, Medtronic just received FDA approval last month for its Simplera Sync CGM system, which is equipped with the MiniMed 780G, to officially launch in the market.

Medtronic's Next-Generation Simplera CGM System Initially Received FDA Approval in August.The Simplera platform includes the Simplera CGM system, which works with the InPen smart insulin pen, and the Simplera Sync system, which is specifically integrated with the MiniMed 780G.Simplera Sync and MiniMed 780G were approved for CE marking in January 2024.